

March 31, 2015



Inogen to File Form 12b-25 With Securities and Exchange Commission

GOLETA, Calif., March 31, 2015 (GLOBE NEWSWIRE) --[Inogen, Inc.](http://www.inogen.com) (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the home care setting, announced today that it will file a Form 12b-25 Notification of Late Filing with the U.S. Securities and Exchange Commission with regard to its Annual Report on Form 10-K for the year ended December 31, 2014. The filing provides the Company with an additional 15 calendar days to file its Form 10-K.

The Company was unable to file its Form 10-K by the March 31, 2015 deadline because the Company has not finalized an ongoing internal investigation regarding certain potential accounting matters that were discovered by management. Specifically, the Audit Committee, with the assistance of independent advisors, is currently investigating whether there were any violations of the Company's accounting policies associated with these potential accounting matters. Consequently, the Company is not in a position to file its Form 10-K until after the completion of the Audit Committee's investigation. However, the Company expects to be able to complete its Form 10-K by the extended deadline of April 15, 2015.

Inogen has used, and intends to continue to use, its Investor Relations website, www.inogen.com/investor, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit www.inogen.com/investor.

About Inogen

Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. For more information, please visit www.inogen.com.

Use of Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the timing and anticipated filing of the Company's 10-K and the timing and completion of and determinations with respect to the Company's audit and the Audit Committee's review. These forward-looking statements involve risks and uncertainties, and actual results could vary materially from these forward-looking statements. Factors that may cause future results to differ materially from management's current expectations include, among other things, the discovery of additional information relevant to the internal investigation; the conclusions of the Audit Committee (and the timing of the conclusions) concerning matters relating to the internal investigation; the timing of the review by, and the conclusions of, our independent

registered public accounting firm regarding the internal investigation and our financial statements; the risk that the completion and filing of the Form 10-K will take longer than expected; and the risk that the Company will be unable to file the Form 10-K within the extension period of 15 calendar days provided under Rule 12b-25 of the Exchange Act.

Information on certain of these risks, uncertainties, and other information affecting Inogen's business and operating results are contained in Inogen's Annual Report on Form 10-K for the year ended December 31, 2013 and in Inogen's subsequent reports on Form 10-Q and Form 8-K. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.

CONTACT: Investor Relations Contact:

ir@inogen.net
805-562-0500 ext. 7

Media Contact:

Byron Myers
805-562-0503

Source: Inogen